eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21days)	capecitabine (1.25g/m2 twice daily on days 1–14 every 21 days)	time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced/metastatic breast cancer (MBC)	-1	-1	In addition, the time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) was also not significantly different between the two treatment arms (HR 0.81; p = 0.12; Fig. 3a).Fig. 1
eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25g/m2 twice daily on days 1–14 every 21 days)	median survival (OS) in patients with no reported disease progression - women with advanced/metastatic breast cancer (MBC)	-1	-1	<td>HR eribulin vs. TPC (95&nbsp;% CI)</td><td colspan="2">0.76 (0.51, 1.12)</td><td>–</td><td colspan="2">0.74 (0.50, 1.10)</td><td>–</td><td colspan="2">0.77 (0.54, 1.10)</td><td>–</td>
eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25 g/m2 twice daily on days 1–14 every 21 days)	time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced/metastatic breast cancer (MBC)	-1	-1	the time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) was also not significantly different between the two treatment arms (HR 0.81; p = 0.12;
eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21days)	capecitabine (1.25g/m2 twice daily on days 1–14 every 21 days)	time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced/metastatic breast cancer (MBC)	-1	-1	the time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) was also not significantly different between the two treatment arms (HR 0.81; p = 0.12
eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25g/m2 twice daily on days 1–14 every 21 days)	Median overall survival (OS) for patients whose disease progressed due to new metastases - women with advanced/metastatic breast cancer (MBC)	18642	18815	Median OS for patients whose disease progressed due to new metastases was significantly longer with eribulin than with capecitabine (14.6 vs. 11.3 months; HR 0.75; p = 0.008
eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25g/m2 twice daily on days 1–14 every 21 days)	median survival (OS) in patients with no reported disease progression - women with advanced/metastatic breast cancer (MBC)	18986	19138	In patients with no reported disease progression, median OS was 17.6 versus 16.8 months (HR 0.91; p = 0.44) for eribulin and capecitabine, respectively.
eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25 g/m2 twice daily on days 1–14 every 21 days)	time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) - women with advanced/metastatic breast cancer (MBC)	-1	-1	the time to new metastases in patients whose disease progressed due to new metastases in vital organs (CNS, lungs, or liver) was also not significantly different between the two treatment arms (HR 0.81; p = 0.12
eribulin mesylate (1.4mg/m2 on days 1 and 8 every 21 days)	capecitabine (1.25 g/m2 twice daily on days 1–14 every 21 days)	new metastases was associated with an increased risk of death - women with advanced/metastatic breast cancer (MBC)	1126	1215	development of new metastases was associated with an increased risk of death (p < 0.0001)
